Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: altretamine Clear all
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 13, 2026, 9:54 AM EDT
Withdrawn Early Phase 1 Interventional

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

NCT03591614
View directory record Official record
Conditions
Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
Interventions
DKK1
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

NCT00063778
View directory record Official record
Conditions
HIV Infections
Interventions
AVX101, placebo
Biological · Other
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Sep 13, 2026, 9:54 AM EDT
Withdrawn Phase 1 Interventional

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

NCT03552796
View directory record Official record
Conditions
Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I
Interventions
Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein
Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 13, 2026, 9:54 AM EDT
Active, not recruiting Phase 1 Interventional

E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

NCT04057833
View directory record Official record
Conditions
Rotator Cuff Tears, Muscle Atrophy or Weakness, Tendon Rupture - Shoulder, Safety Issues
Interventions
E-CEL UVEC
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 13, 2026, 9:54 AM EDT
Not listed Phase 2 Interventional

A Study of sEphB4-HSA in Kaposi Sarcoma

NCT03993106
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
sEphB4-HSA
Drug
Lead sponsor
Vasgene Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Beverly Hills, California • Sarasota, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

NCT00684021
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Phase 1 Interventional

AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint

NCT02762760
View directory record Official record
Conditions
Osteoarthritis of the Hand
Interventions
AMPION™, Saline
Biological
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Sep 13, 2026, 9:54 AM EDT
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Phase 1 Interventional

Altretamine and Etoposide in Treating Patients With HIV-Related Cancer

NCT00002936
View directory record Official record
Conditions
Lymphoma, Sarcoma
Interventions
altretamine, etoposide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 13, 2026, 9:54 AM EDT
Terminated Phase 1 Interventional

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

NCT06035744
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CLN-617, Pembrolizumab
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 13, 2026, 9:54 AM EDT
Recruiting Phase 2Phase 3 Interventional

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

NCT06493552
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
Interventions
SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin, Enfortumab vedotin
Drug
Lead sponsor
Vasgene Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 13, 2026, 9:54 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

NCT05604521
View directory record Official record
Conditions
Malaria, Malaria,Falciparum
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 13, 2026, 9:54 AM EDT
Recruiting Phase 2 Interventional

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

NCT04476901
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
allogeneic human mesenchymal stem cells (hMSCs), Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Stanford, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Phase 1 Interventional

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

NCT02600130
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Longeveron Mesenchymal Stem Cells, Placebo
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)

NCT00824005
View directory record Official record
Conditions
Chronic Ischemic Heart Disease, Left Ventricular Dysfunction, Angina, Ischemic Cardiomyopathy
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

Patients With Intermittent Claudication Injected With ALDH Bright Cells

NCT01774097
View directory record Official record
Conditions
Peripheral Artery Disease, Intermittent Claudication
Interventions
ALD-301, Placebo (vehicle)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Phase 2 Interventional

Interferon-Alpha for Diabetes Mellitus Type 1

NCT00024518
View directory record Official record
Conditions
Insulin-Dependent Diabetes Mellitus
Interventions
30,000 units hrINF-alpha, 5,000 hrINF-alpha, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
5
States / cities
Bethesda, Maryland • Saint Paul, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 13, 2026, 9:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

NCT04442126
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
Interventions
NM21-1480
Biological
Lead sponsor
Numab Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
Fort Collins, Colorado • Augusta, Georgia • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Not applicable Interventional Results available

NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study

NCT01394978
View directory record Official record
Conditions
Lung Cancer, Lung Tumor
Interventions
Control, ProGEL Pleural Air Leak Sealant with standard surgical closure, ProGEL Pleural Air Leak Sealant without standard surgical closure
Other · Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Jacksonville, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 13, 2026, 9:54 AM EDT
Completed Phase 1 Interventional

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

NCT04091867
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
sEphB4-HSA with chemotherapy, Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 13, 2026, 9:54 AM EDT
Active, not recruiting Phase 1 Interventional

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02495896
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Interventions
Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 13, 2026, 9:54 AM EDT
Terminated Phase 1 Interventional

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

NCT03519984
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic/Myeloproliferative Neoplasm, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein, Vincristine Liposomal
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 13, 2026, 9:54 AM EDT
Suspended Phase 1 Interventional

Islet Allotransplantation in Type 1 Diabetes

NCT01705899
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Human Pancreatic Islets
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2033
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 13, 2026, 9:54 AM EDT